Dosage and administration of vepotuzumab (POLIVY)

For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL)Vepotuzumab ( The recommended dose of POLIVY) is 1.8mg/kg, used in combination with rituximab products, cyclophosphamide, doxorubicin and prednisone, as an intravenous infusion every 21 days for a total of 6 cycles. For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), the recommended dose of vepotuzumab is 1.8 mg/kg, used in combination with bendamustine and rituximab products, as an intravenous infusion every 21 days for a total of 6 cycles.